FDA Will Investigate Pharma Promo Caveats, 'Overwarnings'
The U.S. Food and Drug Administration plans to investigate how prescribers use data presented as part of cancer drug promotions, as well as whether "overwarning" consumers will cause them to ignore...To view the full article, register now.
Already a subscriber? Click here to view full article